1. Signaling Pathways
  2. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
    Vitamin D Related/Nuclear Receptor
  3. PPAR

PPAR

Peroxisome proliferator-activated receptors

PPARs (Peroxisome proliferator-activated receptors) are ligand-activated transcription factors of nuclear hormone receptor superfamily comprising of the following three subtypes: PPARα, PPARγ, and PPARβ/δ. PPARs play essential roles in the regulation of cellular differentiation, development, and metabolism (carbohydrate, lipid, protein), and tumorigenesis of higher organisms. All PPARs heterodimerize with the retinoid X receptor (RXR) and bind to specific regions on the DNA of target genes. Activation of PPAR-α reduces triglyceride level and is involved in regulation of energy homeostasis. Activation of PPAR-γ enhances glucose metabolism, whereas activation of PPAR-β/δ enhances fatty acids metabolism.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-117727S
    Leriglitazone-d4
    Antagonist
    Leriglitazone-d4 (MIN-102-d4; Hydroxypioglitazone-d4) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penetrable PPARγ agonist with an EC50 of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases.
    Leriglitazone-d<sub>4</sub>
  • HY-14998
    Halofenate
    Agonist
    Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo.
    Halofenate
  • HY-113631
    Amorfrutin B
    Agonist
    Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with Ki values of 19 nM and EC50 values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities.
    Amorfrutin B
  • HY-17356G
    Fenofibrate (GMP)
    Agonist
    Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
    Fenofibrate (GMP)
  • HY-139058R
    23-epi-26-Deoxyactein (Standard)
    23-epi-26-Deoxyactein (Standard) is the analytical standard of 23-epi-26-Deoxyactein. This product is intended for research and analytical applications. 23-epi-26-Deoxyactein is a natural and orally active anti-obesity and anti-cancer compound.
    23-epi-26-Deoxyactein (Standard)
  • HY-N0059S4
    D-Arabinose-d2
    Activator
    D-Arabinose-d2 is the deuterium labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082).
    D-Arabinose-d<sub>2</sub>
  • HY-121579
    L-764406
    Agonist
    L-764406 is a non-thiazolidinedione (TZD)-type PPARg nuclear receptor ligand with high affinity. L-764406 has significant binding ability to PPARg (IC50=70 nM). L-764406 exhibited partial agonist activity and induced expression of the adipocyte-specific gene aP2 in chimeric receptors expressing the PPARg LBD and the corresponding reporter gene, as well as in 3T3-L1 cells. In contrast, L-764406 showed no activity in cells transfected with chimeric receptors containing PPARa or PPARd LBDs.
    L-764406
  • HY-146731
    PPARγ agonist 1
    Agonist
    PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders.
    PPARγ agonist 1
  • HY-107333
    Cinoxate
    Agonist
    Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with Ki value of 18.0 μM. Cinoxate can be used to study obesity.
    Cinoxate
  • HY-19848
    Cevoglitazar
    Agonist
    Cevoglitazar (LBM-642) is an orally active and highly potent PPARα and PPARγ dual agonist. Cevoglitazar can reduce food intake, body weight, and fasting plasma insulin in obese mice and cynomolgus monkeys. Cevoglitazar has the potential for diabetes and obesity-related disorders research.
    Cevoglitazar
  • HY-100120
    Pparδ agonist 2
    Agonist
    Pparδ agonist 2 is a PPARδ agonist extracted from patent WO 2016057656 A1.
    Pparδ agonist 2
  • HY-173443
    SP-C01
    Agonist
    SP-C01 is an orally active soluble epoxide hydrolase (sEH) inhibitor and partial PPARγ agonist. SP-C01 can inhibit Ser273 phosphorylation.
    SP-C01
  • HY-B0664S
    Ciprofibrate-d6
    Agonist
    Ciprofibrate-d6 is deuterium labeled Ciprofibrate. Ciprofibrate (Win35833) is a potent peroxisome proliferator, increases the phosphorylation level of the PPARalpha.
    Ciprofibrate-d<sub>6</sub>
  • HY-168719
    PPARγ agonist 16
    Agonist
    PPARγ agonist 16 (Compound 4G) is the agonist for PPARγ, that competitively binds to LBD domain of PPARγ with IC50 of 1790 nM. PPARγ agonist 16 inhibits the ear swelling in mouse model, and exhibits anti-hyperglycemic in Streptozotocin (HY-13753)-induced mouse diabetes mellitus model.
    PPARγ agonist 16
  • HY-107217
    Apo-12'-lycopenal
    Activator
    Apo-12'-lycopenal is a Lycopene (HY-N0287) metabolite. Apo-12'-lycopenal promotes adipocyte differentiation and adiponectin secretion via PPAR-γ activation.
    Apo-12'-lycopenal
  • HY-111068
    KD-3010
    Agonist
    KD-3010 is a potent, orally active, and selective PPARδ agonist.
    KD-3010
  • HY-N0059S1
    D-Arabinose-13C-1
    Activator
    D-Arabinose-13C-1 is the 13C labeled D-Arabinose (HY-N0059). D-Arabinose is is an orally active antidepressant and a growth inhibitor of C. elegans (IC50 is 7.5 mM). D-Arabinose can penetrate the blood-brain barrier, selectively interfere with the metabolism of D-ribose and D-fructose, and inhibit the growth of nematodes. D-Arabinose can also inhibit the synthesis of cell biofilm and exert antibacterial activity. D-Arabinose activates the ACSS2-PPARγ/TFEB-CRTC1 axis through the lysosomal AXIN-LKB1-AMPK pathway, inducing CRTC1 transcription, exerts antidepressant-like activity. D-Arabinose is the ring-opened form of the aldopentose D-?Arabinose (HY-N7082).
    D-Arabinose-<sup>13</sup>C-1
  • HY-101064S
    Fmoc-leucine-13C
    99.90%
    Fmoc-leucine-13C is a 13C-labeled Boc-GlycineFmoc-leucine (HY-101064).
    Fmoc-leucine-<sup>13</sup>C
  • HY-W699866
    Gemfibrozil 1-O-β-glucuronide-d6
    Gemfibrozil 1-O-β-glucuronide-d6 is the deuterium labeled Gemfibrozil 1-O-β-glucuronide (HY-129993). Gemfibrozil 1-O-β-Glucuronide, a metabolite of Gemfibrozil (CI-719; HY-B0258), is a potent and competitive P450 (CYP) isoform CYP2C8 inhibitor with an IC50 of 4.07 μM.
    Gemfibrozil 1-O-β-glucuronide-d<sub>6</sub>
  • HY-117103A
    AMG131 benzenesulfonate
    Modulator
    AMG131 (INT131) (benzenesulfonate) is a potent non-thiazolidinedione (TZD) selective peroxisome proliferator-activated receptor γ modulator (SPPARM). AMG131 (benzenesulfonate) binds to PPARγ within the same binding pocket as the TZDs, but occupies a unique space in the pocket and contacts the receptor at distinct points from the TZDs. AMG131 (benzenesulfonate) is promising for research of type-2 diabetes mellitus.
    AMG131 benzenesulfonate
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.